Parkinson disease: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• SNCA 10
• LRRK2 7
• NRF2 1
• GBA1 13
• NLRP3 1
• PINK1 1
• AKT 0
• PI3K 0
• GLP-1 0
• STING 0
• BDNF 1
• mTOR 0
• SIRT1 0
• TLR4 0
• PPAR 0
• AMPK 1
• TP53 0
• GPX4 0
• MAPK 0
• MAPT 0
• APOE 1
• TNF 0
• HMGB1 0
• JNK 0
• ERK 0
• HSP90 1
• STAT3 0
• TREM2 0
• HDAC 0
• JAK 0
• TDP-43 1
• NMDA 0
• TFEB 0
• HIF-1 1
• IL-1 0
• PARP 0
• CTNNB1 0
• GIP 0
• IL-17 0
• PCSK9 0
• ACE2 0
• AQP4 0
• BCL-2 0
• CSF1R 0
• FTO 0
• PKM2 0
• SGLT2 0
• CD38 0
• COX-2 0
• DPP-4 0
• G6PD 0
• IDO1 0
• PDE4 0
• PTEN 0
• YAP 0
• ALK 0
• APP 0
• ATM 0
• BACE1 0
• C9orf72 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 24+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Trials whose registry record says individual participant data (IPD) will be shared.

• Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation

  NCT07642908· University of Michigan· Source

• Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage

  NCT06993142· Radboud University Medical Center· Source

• LRRK2 (Leucine-Rich Repeat Kinase 2) Parkinson's Disease Fingerprint

  NCT07681219· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Source

• LRRK2, GBA and Other Genetic Biomarkers in Eastern European (Ashkenazi) Jews With and Without Parkinson's Disease

  NCT04668898· Icahn School of Medicine at Mount Sinai· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 23
• Organoids 19
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 15
• Gene Expression Profiling 75
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 7
• Exome Sequencing 12
• Proteomics 70
• Metabolomics 34
• Mass Spectrometry 12
• Flow Cytometry 4
• Immunohistochemistry 50
• Liquid Biopsy 3
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 100
• Magnetic Resonance Imaging 366
• Machine Learning 141
• Deep Learning 72
• Cohort Studies 184
• Genome-Wide Association Study 83

• Identification and validation of biomarkers associated with mitochondrial dynamics dysfunction in Parkinson's disease based on GEO datasets.

  PLoS One, Nov 2026

• Identification and experimental validation of candidate biomarkers for Parkinson's Disease through integrated bioinformatics, Mendelian randomization, and machine learning.

  Mol Biol Rep, Oct 2026

• Single-cell transcriptomic analysis reveals autophagy-associated transcriptional vulnerability of dopaminergic neurons after atrazine exposure.

  Ecotoxicol Environ Saf, Oct 2026

• A transcriptomic resilience gap between the substantia nigra and cerebellum is associated with regional vulnerability in Parkinson's disease.

  Biochem Biophys Res Commun, Oct 2026

• Integrative Genetic and Transcriptomic Analysis Reveals Candidate Molecular Differences Among Dementia with Lewy Bodies, Alzheimer's Disease, and Parkinson's Disease Dementia.

  Int J Mol Sci, Oct 2026

• Exploring the Potential Neurotoxic Links Between 6PPD/6PPD-Q and Parkinson's Disease Through Network Toxicology and Multi-Dimensional Bioinformatics Analysis.

  Neurotox Res, Oct 2026

• Bioactivated Glucoraphanin Exerts a Potential Protective Effect in an In Vitro Model of Parkinson's Disease: A Transcriptomic Study.

  Int J Mol Sci, Sept 2026

• Cuproptosis-associated genes DLD, ULK2, CCL8, and CCS link metabolic and immunological dysfunction in Parkinson's disease: a multi-omics study.

  Front Immunol, Sept 2026

• Batch- and Composition-Controlled Reanalysis of Bulk and Single-Nucleus Transcriptomes Reveals Co-Enrichment of Glial Complement and of Translational Signatures in Parkinson's Disease and Amyotrophic Lateral Sclerosis.

  Int J Mol Sci, Sept 2026

• ACE2 and Parkinsonism‑related bone metabolic alterations: signaling pathways and hub gene analysis.

  Mol Genet Genomics, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.